Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer of the target KIR3DL2, will present the rationale of IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody for the treatment of CTCL, as well as the protocol of the upcoming Phase I trial at the EORTC cutaneous lymphoma task force meeting (September 25-27, 2015 in Turin, Italy).
Presentation title: “A novel targeted immunotherapy for CTCL: anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies”
Session Name: Neil-Smith memorial lecture
Date: Saturday, September 26, 2015
Presentation Time: 12:30 AM – 1:00 PM
The presentation will be available at its public presentation on Innate Pharma’s website.
****
Innate Pharma will host a Key Opinion Leader luncheon to discuss Cutaneous T-cell Lymphoma on Friday, October 2, 2015, in New York.
Youn H. Kim, MD, Professor of Dermatology, Director of Multidisciplinary Cutaneous Lymphoma Program and Medical Director of Photopheresis Service at the Stanford Medical Center will lead the discussion.
This event is intended for institutional investors and sell-side analysts. To reserve a place, please contact Mac MacDonald at 212-915-2567 or via e-mail at mac@lifesciadvisors.com.
| PR in English | 74.18 KB |
| CP en français | 35.78 KB |